8-K: Myomo Announces $6 Million Registered Direct Offering and Preliminary Q4 Results

Myomo, Inc. has announced a $6 million registered direct offering to scale operations for Medicare Part B patients, alongside preliminary Q4 revenue of $4.6 to $4.8 million and a backlog of 230 patients.

Summary

• Myomo, Inc. has entered into a securities purchase agreement for a registered direct offering, selling 1,578,948 shares of common stock (or equivalents) at $3.80 per share, raising approximately $6 million before expenses.
• The company intends to use the net proceeds to scale up operations for Medicare Part B patients, including hiring about 50 people over the next six months.
• Myomo reported preliminary fourth-quarter 2023 revenue between $4.6 million and $4.8 million, a 14% to 19% increase year-over-year.
• The company's cash balance was approximately $8.7 million as of December 31, 2023.
• Myomo's backlog as of December 31, 2023, was approximately 230 patients, a 40% increase compared to the previous year.
• The company aims to achieve at least $100 million in annual revenues within the next five years.
• The offering is expected to close around January 19, 2024, subject to customary conditions.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative aspects. The capital raise and revenue growth are positive, but the company's history of losses and dependence on external financing temper the overall sentiment. The focus on Medicare Part B is a positive catalyst, but execution risks remain.

Positives

• The company has secured $6 million in funding through a registered direct offering.
• Myomo is experiencing significant revenue growth, with a 14% to 19% increase expected in Q4 2023.
• The patient backlog has increased by 40%, indicating strong demand for MyoPro devices.
• The company is scaling up operations to serve the Medicare Part B market, which is expected to be a major growth driver.
• Myomo anticipates achieving cash flow breakeven by the fourth quarter of 2024.

Negatives

• The company has a history of operating losses and has previously expressed substantial doubt about its ability to continue as a going concern.
• The company is dependent on external sources for financing its operations.
• The company's revenue is concentrated with a particular insurance payer.
• The company is subject to supply chain risks that could disrupt operations.

Risks

• The company's ability to obtain sufficient reimbursement from third-party payers, including CMS for Medicare Part B patients, is a risk.
• The company's revenue concentration with a particular insurance payer is a risk.
• Supply chain disruptions could impact the company's ability to deliver and fit its custom-fabricated devices.
• The company's dependence on external financing is a risk if it does not achieve or maintain cash flow breakeven.
• The company's ability to effectively execute its business plan and scale up operations is a risk.
• General market, economic, environmental, and social factors could affect the evaluation, fitting, delivery, and sale of the company's products.

Future Outlook

Myomo expects to achieve cash flow breakeven on a quarterly basis by the fourth quarter of 2024, assuming CMS final fee is not significantly lower than the proposed fee, the company can hire the necessary personnel, and there are no unusual supply chain disruptions. The company also aims to achieve at least $100 million in annual revenues within the next five years.

Management Comments

• We've begun deliveries of our MyoPro device to Medicare Part B beneficiaries, a patient population we expect to be a significant driver of revenue growth in 2024, stated Paul R. Gudonis, Myomos Chairman and CEO.
• With this anticipated major increase in our addressable market, our aspiration is to achieve at least $100 million in annual revenues within the next five years.

Industry Context

The announcement comes as Myomo is expanding its reach into the Medicare Part B market, which represents a significant opportunity for growth in the wearable medical robotics sector. The company's focus on reimbursement and scaling operations aligns with industry trends in healthcare technology.

Comparison to Industry Standards

• Myomo's revenue growth of 14% to 19% in Q4 2023 is a positive sign, but it is important to compare this to other companies in the medical device and robotics industry.
• Companies like Ekso Bionics and ReWalk Robotics, which also focus on wearable robotics, have faced challenges in achieving profitability and widespread adoption.
• Myomo's ability to secure Medicare Part B reimbursement is a key differentiator, but the company must demonstrate consistent revenue growth and efficient scaling of operations to compete effectively.
• The target of $100 million in annual revenue within five years is ambitious and will require significant market penetration and successful execution of the company's business plan.

Stakeholder Impact

• Shareholders will experience dilution from the new share issuance.
• Employees may benefit from the hiring of 50 new personnel.
• Customers (patients) will benefit from the increased capacity to serve Medicare Part B beneficiaries.
• Suppliers may see increased demand for components and materials.
• Creditors may be concerned about the company's history of losses and dependence on external financing.

Next Steps

• The company will close the offering around January 19, 2024.
• Myomo will hire approximately 50 new employees over the next six months.
• The company will report financial results for the fourth quarter and year ended December 31, 2023 before March 15, 2024.

Key Dates

Keywords

Myomo, MyoPro, registered direct offering, Medicare Part B, wearable robotics, neurological disorders, upper-limb paralysis, revenue, backlog, cash flow breakeven, medical devices, healthcare